Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized treatment and survival outcomes across a diverse spectrum of solid and hematological malignancies. These paradigm-shifting agents display unique mechanisms of action, response patterns, and safety profiles, all of which differ greatly from more conventional chemotherapy and targeted therapies. As a result, implementing checkpoint inhibitors in clinical practice requires healthcare practitioners to adopt specialized administration, efficacy assessment, and immunemediated adverse reactions (imARs) management strategies. Furthermore, appropriate patient counseling and education remains critical to promote prompt recognition of imARs. This archived educational session will present the most up-to-date evidence on immunotherapy treatment options, cover a wide range of checkpoint inhibitor indications, and discuss clinically relevant strategies to effectively utilize these agents in practice.